Brexit goes real – What’s next for Pharma and Medtech
Since 1 January 2021, new requirements apply for the authorization of medicines and medical devices in the UK and for the trade between the EU and the UK, and special regulations apply to Northern Ireland which is both part of the UK as well as the EU’s single market.
SFL has long-standing experience in supporting UK- and EU-based companies in all aspects of drug and device product lifecycle.
- SFL’s EU office can support UK-based companies to establish their presence and products in the EU and comply with EU regulations
- SFL’s UK office can support EU-based companies in submitting applications to MHRA to support the licensing and marketing of their drugs and devices
Contact us at email@example.com to arrange a call to discuss how SFL can support your company to adapt to the regulatory changes for drugs and devices in the UK and in the EU.